Literature DB >> 16116591

Ovarian cancer: can we make the clinical diagnosis earlier?

Lloyd H Smith1, Cyllene R Morris, Shagufta Yasmeen, Arti Parikh-Patel, Rosemary D Cress, Patrick S Romano.   

Abstract

BACKGROUND: Patients with ovarian cancer often report having symptoms for months before diagnosis, but such findings are subject to recall bias. The aim of this study was to provide an objective evaluation of symptoms that precede a diagnosis of ovarian cancer.
METHODS: Medicare provider claims linked to records in the California Surveillance, Epidemiology, and End Results data base were utilized to extract diagnosis and procedure codes for 1985 women age 68 years or older who resided in California with ovarian cancer, 6024 elderly women with localized breast cancer, and 10,941 age-matched, Medicare-enrolled women without cancer. Prevalence of rates of symptom-related diagnoses and procedure codes in Medicare claims records were obtained during 3-month periods up to 36 months before diagnosis of ovarian cancer.
RESULTS: From 1 month to 3 months before patients were diagnosed with ovarian cancer, the frequency and adjusted odds ratios (ORs) with 95% confidence intervals (95%CIs) for 4 "target symptom" code groups were: abdominal pain (frequency, 30.6%; OR, 6.0; 95%CI, 5.1-6.9), abdominal swelling (frequency, 16.5%; OR, 30.9; 95%CI, 21.4-44.8), gastrointestinal symptoms (frequency, 8.4%; OR, 2.3; 95%CI, 1.8-3.0), and pelvic pain (frequency, 5.4%; OR, 4.3; 95%CI, 2.8-6.7). The adjusted odds for abdominal swelling codes was elevated 10-12 months before diagnosis (OR, 2.4; 95%CI, 1.2-4.6) for abdominal pain codes 7-9 months before diagnosis (OR, 1.3; 95%CI, 1.1-1.7). Abdominal imaging (frequency, 7.0%; OR, 1.3; 95%CI, 1.0-1.7) and pelvic imaging/CA125 (frequency, 3.7%; OR, 2.4; 95%CI, 1.7-3.4) showed an elevated frequency and adjusted odds 4-6 months before diagnosis. Patients with claims codes for "target symptoms" 4-36 months before diagnosis were more likely to have abdominal imaging (61.1%) or gastrointestinal procedures (30.8%) than pelvic imaging/CA125 (25.3%).
CONCLUSIONS: Patients with ovarian cancer were more likely than patients with breast cancer and women in a cancer-free control group to have target symptom codes (particularly abdominal swelling and pain) > 6 months before diagnosis. The evaluation of women with unexplained "target symptoms" should include pelvic imaging and/or CA125.

Entities:  

Mesh:

Year:  2005        PMID: 16116591     DOI: 10.1002/cncr.21310

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  A national initiative for women and healthcare providers: CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer campaign.

Authors:  Sun Hee Rim; Lindsey Polonec; Sherri L Stewart; Cynthia A Gelb
Journal:  J Womens Health (Larchmt)       Date:  2011-09-20       Impact factor: 2.681

2.  Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK.

Authors:  Bei Zhang; Xueya Wang; Fengfeng Cai; Weijie Chen; Uli Loesch; Johannes Bitzer; Xiao Yan Zhong
Journal:  Tumour Biol       Date:  2012-07-07

3.  Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability.

Authors:  Barbara A Goff; Kimberly A Lowe; Jeannette C Kane; Marissa D Robertson; Marcia A Gaul; M Robyn Andersen
Journal:  Gynecol Oncol       Date:  2011-11-06       Impact factor: 5.482

Review 4.  A terrible beauty: a physician's story of ovarian cancer.

Authors:  Linda J Spano
Journal:  Can Fam Physician       Date:  2007-06       Impact factor: 3.275

5.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

6.  Estimating the Prevalence of Ovarian Cancer Symptoms in Women Aged 50 Years or Older: Problems and Possibilities.

Authors:  Zhuoyu Sun; Lucy Gilbert; Antonio Ciampi; Jay S Kaufman; Olga Basso
Journal:  Am J Epidemiol       Date:  2016-10-13       Impact factor: 4.897

7.  Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK.

Authors:  Nathan M Weir; Karuppaiyah Selvendiran; Vijay Kumar Kutala; Liyue Tong; Shilpa Vishwanath; Murugesan Rajaram; Susheela Tridandapani; Shrikant Anant; Periannan Kuppusamy
Journal:  Cancer Biol Ther       Date:  2007-02-05       Impact factor: 4.742

8.  Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.

Authors:  M Montopoli; E Ragazzi; G Froldi; L Caparrotta
Journal:  Cell Prolif       Date:  2009-02-18       Impact factor: 6.831

9.  Ovarian cancer pathogenesis: a model in evolution.

Authors:  Alison M Karst; Ronny Drapkin
Journal:  J Oncol       Date:  2009-09-06       Impact factor: 4.375

10.  Risk of ovarian cancer in women with symptoms in primary care: population based case-control study.

Authors:  William Hamilton; Tim J Peters; Clare Bankhead; Deborah Sharp
Journal:  BMJ       Date:  2009-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.